title: Enteroviral and immune mediated myocarditis in SCID mice.
abstract: Severe combined immune deficiency (SCID) mice have been used as an animal model to study both the direct cytopathic effect of enteroviruses on the heart in the absence of an effective immune system and to investigate the role of immune mediated processes in the pathogenesis of human myocarditis. The infection of SCID mice with coxsackievirus B3 resulted in severe myocarditis with very high titers of the virus in the myocardium and severe necrosis of myocytes. This direct cytopathic effect caused an impairment of the myocardial function and resulted in a high mortality rate of the infected animals. For the study of the immune mechanisms in human myocarditis, peripheral blood leukocytes of patients with myocarditis, having an impaired left ventricular function without viral persistence in the myocardium, were transferred into SCID mice. As controls peripheral blood leukocytes of normal donors were used. At 60 days after transfer, human immunoglobulines could be demonstrated in the peripheral blood of the SCID mice, however, human autoantibodies against the adenine nucleotide translocator, a myocardial autoantigen, were only present in the animals receiving peripheral blood leukocytes from patients with myocarditis. Cellular infiltrates of human leukocytes in the myocardium and an impaired left ventricular function were also only observed in animals reconstituted with peripheral blood leukocytes from patients. These effects were T cell dependent as shown by differential transfer. These results are of interest for the treatment of human myocarditis, suggesting the avoidance of an immunosuppressive therapy in acute or chronic myocarditis with viral persistence to prevent a direct cytopathic effect in the absence of an effective immune system. However, in the setting of a chronic, (auto-)immunological myocarditis with the proven absence of entero- or adenoviral sequences an immunomodulatory therapy seems to be effective and safe.
authors.affiliation: Department of Internal Medicine/Cardiology, Benjamin Franklin Hospital, Free University Berlin, Germany. Schwimmbeck@ukbf.fu-berlin.de
authors.forename: P L
authors.initials: PL
authors.lastname: Schwimmbeck
authors.forename: G
authors.initials: G
authors.lastname: Rohn
authors.forename: A
authors.initials: A
authors.lastname: Wrusch
authors.forename: K
authors.initials: K
authors.lastname: Schulze
authors.forename: A
authors.initials: A
authors.lastname: Doerner
authors.forename: U
authors.initials: U
authors.lastname: Kuehl
authors.forename: C
authors.initials: C
authors.lastname: Tschoepe
authors.forename: M
authors.initials: M
authors.lastname: Pauschinger
authors.forename: H P
authors.initials: HP
authors.lastname: Schultheiss
mesh_terms: D000818:Animals; D001323:Autoantibodies / Q000097:blood; D001327:Autoimmune Diseases / Q000276:immunology* / Q000473:pathology; D003384:Coxsackievirus Infections / Q000276:immunology* / Q000473:pathology; D003588:Cytopathogenic Effect, Viral; D004195:Disease Models, Animal; D029822:Enterovirus B, Human / Q000276:immunology*; D006801:Humans; D008297:Male; D051379:Mice; D016513:Mice, SCID; D009205:Myocarditis / Q000276:immunology* / Q000473:pathology; D009206:Myocardium / Q000276:immunology / Q000473:pathology; D013601:T-Lymphocytes / Q000276:immunology / Q000473:pathology
chemical_list: D001323:Autoantibodies